New steroid hope for duchenne boys: safer muscle treatment?

NCT ID NCT05185622

Completed Disease control Sponsor: Santhera Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called vamorolone in 54 boys with Duchenne muscular dystrophy, aged 2 to under 4 years and 7 to under 18 years. The goal was to check safety and how the body processes the drug over 12 weeks. Researchers hope vamorolone may help control the disease with fewer side effects than current steroids.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vamorolone
What this could lead to: If successful, vamorolone could offer a safer steroid option for managing Duchenne muscular dystrophy with fewer side effects.
What could go wrong: This is an early Phase 2 trial with only 54 participants, so results may not confirm effectiveness or safety for all. Side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Duchenne muscular dystrophy muscular dystrophy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DUCHENNE MUSCULAR DYSTROPHY

Contacts and locations

Locations

Alberta's Children Hospital

Calgary, Alberta, AB T3B 6A8, Canada
British Columbia Children's Hospital

Vancouver, British Columbia, V6H 3N1, Canada
Children's Hospital of Eastern Ontario

Ottawa, Ontario, K1H 8L1, Canada
Montreal Childrens Hospital

Montreal, H4A 3J1, Canada
The Hospital for Sick Children

Toronto, Ontario, M5G 1X8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.